Results 11 to 20 of about 1,069 (160)

Congenital Hypofibrinogenemia in a Neonate with a Novel Mutation in the FGB Gene [PDF]

Pediatric Reports, 2021
Detection of severe hypofibrinogenemia (
Jun Shinozuka, Nobuo Okumura, Mayumi Nagasawa, Motokazu Nishikado, Sayaka Kadowaki, Itsuro Katsuda, Shinsaku Imashuku   +6 more
doaj   +2 more sources

Thromboelastography as an early prediction method for hypofibrinogenemia in emergency department patients with primary postpartum hemorrhage

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
Background Timely and accurate assessment of coagulopathy is crucial for the management of primary postpartum hemorrhage (PPH). Thromboelastography (TEG) provides a comprehensive assessment of coagulation status and is useful for guiding the treatment of
Sang-Min Kim, Chang Hwan Sohn, Hyojeong Kwon, Seung Mok Ryoo, Shin Ahn, Dong Woo Seo, Won Young Kim   +6 more
doaj   +2 more sources

Hereditary hypofibrinogenemia in primary care pediatrics: a case report

Acta Biomedica Scientifica
Introduction. Hypofibrinogenemia is a rare coagulation disorder characterized by reduced plasma fibrinogen levels and an increased risk of hemorrhagic complications.
M. V. Gomellya, T. S. Krupskaya, T. Yu. Belkova, A. N. Vorzhеva, A. V. Mironova   +4 more
doaj   +2 more sources

SEVERE HYPOFIBRINOGENEMIA IN A PATIENT WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB: CASE-BASED REVIEW [PDF]

Anti-Aging Eastern Europe, 2023
The Giant cell arteritis (GCA) is the most common form of systemic vasculitis in elderly patients. The treatment includes high doses of steroids and interleukin (IL)-6 inhibitor tocilizumab, especially in refractory or relapsing disease or in cases where
Željka Kardum, Ana Šimac, Kristina Frketić Marović, Ana Marija Masle, Jasminka MIlas Ahić   +4 more
doaj   +2 more sources

Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies [PDF]

Haematologica
Chimeric antigen receptor (CAR-) T cell therapy causes serious side effects including cytokine release syndrome (CRS). CRS-related coagulopathy is associated with hypofibrinogenemia that is thus far considered the result of disseminated intravascular ...
Markus Perl, Konstantin Herfeld, Dennis C. Harrer, Matthias Höpting, Marina Schweiger, Ulrich Sterz, Leonard Knödler, Susanne Heimerl, Leo Hansmann, Wolfgang Herr, Hendrik Poeck, Daniel Wolff, Matthias Edinger, Christina Hart, Matthias A. Fante   +14 more
doaj   +4 more sources

Development and validation of a risk prediction model for tigecycline-induced hypofibrinogenemia in septic patients: a retrospective cohort study

BMC Infectious Diseases
Background Tigecycline is widely used in China to treat multidrug-resistant bacterial infections, with hypofibrinogenemia being the most common adverse effect due to its impact on coagulation.
Hongling Ma, Zhaotang Gong, Jia Sun, LiNa Chen, GuLeng SiRi   +4 more
doaj   +2 more sources

Acquired hypofibrinogenemia: current perspectives

Journal of Blood Medicine, 2016
Acquired hypofibrinogenemia is most frequently caused by hemodilution and consumption of clotting factors. The aggressive replacement of fibrinogen has become one of the core principles of modern management of massive hemorrhage. The best method for determining the patient's fibrinogen level remains controversial, and particularly in acquired ...
Besser,Martin, MacDonald,Stephen
openaire   +5 more sources

Transient hypofibrinogenemia due to allopurinol

Drug Design, Development and Therapy, 2014
This study reports a case of an 80-year-old male who suffered from drug eruption due to oral allopurinol for the treatment of gout. This patient complained of widespread erythema and maculopapule with itch, and small quantities of purplish-red rash with diffused distribution on four limbs were noted.
Yin, ZhiQiang, Xu, JiaLi, Li, YongQiang, Xia, JiPing, Luo, Dan   +4 more
openaire   +4 more sources

Severe haemorrhagic diathesis due to acquired hypofibrinogenemia in a patient with early T-cell precursor acute lymphoblastic leukaemia/lymphoma: a case report [PDF]

Frontiers in Cardiovascular Medicine, 2023
The most frequent haematological malignancy associated with acquired hypo/dysfibrinogenemia is multiple myeloma. We present an unusual case of severe haemorrhagic diathesis due to acquired hypofibrinogenemia in a patient with early T-cell precursor acute
Luca Spiezia, Marcello Riva, Carmela Gurrieri, Elena Campello, Paolo Simioni   +4 more
doaj   +2 more sources

A nomogram based on LASSO-logistic regression for predicting tocilizumab-associated hypofibrinogenemia in patients with rheumatic diseases

Frontiers in Pharmacology
IntroductionTocilizumab (TCZ), an IL-6 receptor inhibitor used in rheumatic diseases, can suppress fibrinogen synthesis and cause hypofibrinogenemia, yet its incidence, risk factors and predictive tools remain incompletely characterized.
Chunmei Dai, Chunmei Dai, Yiting Wang, Yiting Wang, Yilei Chen, Jingwen Xie, Jingwen Xie, Zhuoling Zheng, Zhuoling Zheng, Jianlin Huang, Jianlin Huang, Xiaoyan Li, Xiaoyan Li   +12 more
doaj   +2 more sources